MA32945B1 - Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique - Google Patents

Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique

Info

Publication number
MA32945B1
MA32945B1 MA33989A MA33989A MA32945B1 MA 32945 B1 MA32945 B1 MA 32945B1 MA 33989 A MA33989 A MA 33989A MA 33989 A MA33989 A MA 33989A MA 32945 B1 MA32945 B1 MA 32945B1
Authority
MA
Morocco
Prior art keywords
substituted
preparation
treatment
tetrahydroperan
biperidenone
Prior art date
Application number
MA33989A
Other languages
Arabic (ar)
English (en)
Inventor
Zhongli Gao
Ryan Hartung
David Stefany
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA32945B1 publication Critical patent/MA32945B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION ET CONCERNE UNE SÉRIE DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE DE FORMULE (I) DANS LAQUELLE: R1, R2, M, N ET P SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. D'UNE MANIÈRE PLUS SPÉCIFIQUE, LES COMPOSÉS SELON L'INVENTION SONT DES MODULATEURS DES RÉCEPTEURS H3 ET SONT DONC UTILES EN TANT QU'AGENT PHARMACEUTIQUES, NOTAMMENT DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE DIVERSES MALADIES MODULÉES PAR LES RÉCEPTEURS H3 COMPRENANT LES MALADIES ASSOCIÉES AU SYSTÈME CENTRAL NERVEUX. EN OUTRE, LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS ET DES INTERMÉDIAIRES UTILISÉS À CET EFFET.
MA33989A 2008-12-05 2009-12-04 Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique MA32945B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12008708P 2008-12-05 2008-12-05
FR0955909 2009-08-28
PCT/US2009/066666 WO2010065798A1 (fr) 2008-12-05 2009-12-04 Pyrrolidinone et pipéridinone spiro à substitution de tétrahydropyranne, sa preparation et son utilisation thérapeutique

Publications (1)

Publication Number Publication Date
MA32945B1 true MA32945B1 (fr) 2012-01-02

Family

ID=41665099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33989A MA32945B1 (fr) 2008-12-05 2009-12-04 Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique

Country Status (27)

Country Link
US (2) US8217052B2 (fr)
EP (1) EP2373659B1 (fr)
JP (1) JP5410544B2 (fr)
KR (1) KR101682889B1 (fr)
CN (1) CN102239170B (fr)
AR (1) AR074467A1 (fr)
AU (1) AU2009322243B2 (fr)
CA (1) CA2745715C (fr)
CO (1) CO6390059A2 (fr)
CR (1) CR20110289A (fr)
DO (1) DOP2011000166A (fr)
EC (1) ECSP11011109A (fr)
ES (1) ES2507574T3 (fr)
HN (1) HN2011001487A (fr)
IL (1) IL213292A (fr)
MA (1) MA32945B1 (fr)
MX (1) MX2011004791A (fr)
MY (1) MY150789A (fr)
NZ (1) NZ593150A (fr)
PA (1) PA8852301A1 (fr)
PE (1) PE20110773A1 (fr)
RU (1) RU2519778C2 (fr)
TN (1) TN2011000223A1 (fr)
TW (1) TWI441826B (fr)
UA (1) UA104880C2 (fr)
WO (1) WO2010065798A1 (fr)
ZA (1) ZA201103261B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
AR081498A1 (es) 2010-05-11 2012-09-19 Sanofi Aventis Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos
EP2569294B1 (fr) 2010-05-11 2015-03-11 Sanofi Bipyrrolidine carboxamides n-heteroaromatiques, leur preparation et usage therapeutique
EP2569297A1 (fr) 2010-05-11 2013-03-20 Sanofi Dérivés de n-hétérocycloalkyl-bipyrrolidinylphénylamide substitués, préparation et utilisation thérapeutique de ceux-ci
WO2011143148A1 (fr) * 2010-05-11 2011-11-17 Sanofi Bipyrrolidines n-hétéroaryl spirolactame substituées, procédé de préparation et usage thérapeutique associés
EP2569280B1 (fr) 2010-05-11 2015-02-25 Sanofi Phényl-cycloalkyl-pyrrolidine- (pipéridine-) spirolactames et amides substituées, leur préparation et utilisation thérapeutique
TW201206898A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206444A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256276A (en) * 1961-02-17 1966-06-14 Geschickter Fund Med Res Substituted spiroimides
US3258276A (en) 1964-04-06 1966-06-28 Charles E Murcott Utility chair
WO2003031432A1 (fr) * 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
US6889262B1 (en) 2002-06-26 2005-05-03 Advanced Micro Devices, Inc. Direct transaction mode for peripheral devices
EP1556046A1 (fr) * 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
ATE547404T1 (de) * 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
MX2007016216A (es) * 2005-07-01 2008-03-11 Lilly Co Eli Agenes del receptor de histamina h3, preparacion y usos terapeuticos.
ES2381205T3 (es) * 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
ES2344077T3 (es) 2005-12-16 2010-08-17 F.Hoffmann-La Roche Ag Derivados de pirrolo(2,3-b)piridina como moduladores del receptor h3.
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
EP2038256A1 (fr) * 2006-05-23 2009-03-25 TransTech Pharma, Inc 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament
CA2656089A1 (fr) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Composes de benzylamine substituee
WO2009039431A2 (fr) 2007-09-21 2009-03-26 Neurogen Corporation Amines spirocycliques aryl-condensées substituées
ES2372332T3 (es) * 2007-10-17 2012-01-18 Sanofi N-fenil-bipirrolidina carboxamidas sustituidas y su uso terapéutico.
EP2205558B1 (fr) 2007-10-17 2012-07-25 Sanofi Amides de n-phényl-pyrrolidinylméthylpyrrolidine substitués et leur utilisation thérapeutique comme modulateurs du récepteur h3 de l'histamine
SI2212282T1 (sl) 2007-10-17 2012-01-31 Sanofi Sa Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

Also Published As

Publication number Publication date
CN102239170A (zh) 2011-11-09
WO2010065798A1 (fr) 2010-06-10
RU2011127382A (ru) 2013-01-10
UA104880C2 (uk) 2014-03-25
NZ593150A (en) 2012-10-26
EP2373659A1 (fr) 2011-10-12
HN2011001487A (es) 2013-12-02
CR20110289A (es) 2011-09-21
US20110251225A1 (en) 2011-10-13
TWI441826B (zh) 2014-06-21
US20120238757A1 (en) 2012-09-20
US8217052B2 (en) 2012-07-10
CO6390059A2 (es) 2012-02-29
CN102239170B (zh) 2014-08-20
KR20110095911A (ko) 2011-08-25
US8383814B2 (en) 2013-02-26
RU2519778C2 (ru) 2014-06-20
TW201033219A (en) 2010-09-16
MY150789A (en) 2014-02-28
KR101682889B1 (ko) 2016-12-06
CA2745715C (fr) 2014-01-28
JP2012511011A (ja) 2012-05-17
AU2009322243A1 (en) 2011-06-23
DOP2011000166A (es) 2011-10-31
TN2011000223A1 (en) 2012-12-17
CA2745715A1 (fr) 2010-06-10
IL213292A0 (en) 2011-07-31
ECSP11011109A (es) 2011-11-30
AU2009322243B2 (en) 2015-07-16
EP2373659B1 (fr) 2014-07-30
AR074467A1 (es) 2011-01-19
JP5410544B2 (ja) 2014-02-05
PA8852301A1 (es) 2010-07-27
MX2011004791A (es) 2011-05-30
ZA201103261B (en) 2012-01-25
PE20110773A1 (es) 2011-10-26
ES2507574T3 (es) 2014-10-15
IL213292A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
EA201100299A1 (ru) Органические соединения
EA201270575A1 (ru) Соединения
EA201170772A1 (ru) Органические соединения
MA32811B1 (fr) Nouveaux composés
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
EA201190293A1 (ru) Пролекарства триптолида
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA32505B1 (fr) 5-alcynyl-pyrimidines